# UNITED STATES SECURITIES EXCHANGE COMMISSION Washington, D.C. 20549


SCHEDULE 13G (Amendment No. 4)

**Under the Securities Exchange Act of 1934** 

Oramed Pharmaceuticals, Inc. (Name of Issuer)

<u>Common Stock</u> (Title of Class of Securities)

> 68403P104 (CUSIP Number)

<u>December 31, 2013</u>
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[ ]	Rule 13d-1(b)
[X]	Rule 13d-1(c)
[ ]	Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Continued on following pages

<sup>\*</sup> The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

1	NAME OF REPORTING PERSONS			
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)			
	Regals Capital Management LP			
2	CHECK THE A	PPROPRIAT	TE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
	(a) [ ] (b) [ ]			
2	SEC USE ONLY			
3	SEC OSE OIVE.	L		
4	CITIZENSHIP (	CITIZENSHIP OR PLACE OF ORGANIZATION		
	Delaware			
NUMBI	ER OF	5	SOLE VOTING POWER	
SHAI	RES		None	
BENEFIC	CIALLY	6	SHARED VOTING POWER	
OWNED BY			1,376,385	
EAC	СН	7	SOLE DISPOSITIVE POWER	
REPORTING			None	
PERSON		8	SHARED DISPOSITIVE POWER	
WIT	ГН		1,376,385	
9	AGGREGATE A	AMOUNT B	ENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,376,3	885		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]			
	DED CENTE OF	OL A GG DED		
11		LLASS REP	RESENTED BY AMOUNT IN ROW (9)	
	13.4%			
12	TYPE OF REPORTING PERSON (See Instructions)			
	PN			

1	NAME OF REP	ORTING PE	ERSONS	
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)			
	Regals Fund LP			
2	CHECK THE A	.PPROPRIAT	TE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
	(a) [ ] (b) [ ]			
3	SEC USE ONLY			
		00.00		
4	CITIZENSHIP	OR PLACE (	OF ORGANIZATION	
	Delaware			
NUMBE	R OF	5	SOLE VOTING POWER	
SHAF	RES		None	
BENEFIC	CIALLY		CHARLED VOTING POWER	
		6	SHARED VOTING POWER	
OWNE	D BY		1,376,385	
EAC	Н	7	SOLE DISPOSITIVE POWER	
REPOR	TING	-	None	
PERSON			None	
		8	SHARED DISPOSITIVE POWER	
WIT	Ή		1,376,385	
	ACCDECATE	A MOLINIT D	ENEFICIALLY OWNED BY EACH REPORTING PERSON	
9			ENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,376,3	385		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	13.4%			
12	TYPE OF REPORTING PERSON (See Instructions)			
	PN			

4	NAME OF REP	ODTING DE	EDSONS	
1	NAME OF KEP	OKIING PI	ERSOINS	
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)			
	D : 114 Gl			
	David M. Slage	!		
2	CHECK THE A	PPROPRIA	TE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
			(a) [] (b) []	
	( <b>b</b> ) [ ]			
3	SEC USE ONLY	Ĭ.		
4	CITIZENSHIP (	OR PLACE	OF ORGANIZATION	
7				
	Dutch			
NUMBE	ER OF	5	SOLE VOTING POWER	
SHAF	OFS.		None	
31L11	Œ5		Tone	
BENEFIC	CIALLY	6	SHARED VOTING POWER	
OWNE	D BY		1,376,385	
7.4.6			1,57 0,505	
EAC	JH .	7	SOLE DISPOSITIVE POWER	
REPOR	TING		None	
PERSON =			1.00.0	
PERSON		8	SHARED DISPOSITIVE POWER	
WIT	TH		1,376,385	
			1,07 0,000	
9	AGGREGATE A	AMOUNT B	ENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,376,3	85		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
11	PERCENT OF (	CLASS REP	RESENTED BY AMOUNT IN ROW (9)	
	13.4%			
12	TYPE OF REPORTING PERSON (See Instructions)			
	IN			

This Amendment No. 4 is filed with respect to the shares of Common Stock (as defined below) of Oramed Pharmaceuticals, Inc. beneficially owned by the Reporting Persons (as defined below) as of February 6, 2014, and amends and restates the initial Schedule 13G filed by the Reporting Persons on April 13, 2012, as previously amended.

#### Item 1(a). Name of Issuer:

Oramed Pharmaceuticals, Inc. (the "Issuer").

#### Item 1(b). Address of Issuer's Principal Executive Offices:

Hi-Tech Park 2/5 Givat-Ram PO Box 39098 Jerusalem 91390 Israel

#### Item 2(a). Name of Person Filing

This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):

- i) Regals Capital Management LP ("Regals Management"), which serves as investment manager to Regals Fund LP ("Regals Fund") with respect to the shares of Common Stock (as defined in Item 2(d) below) directly owned by Regals Fund;
- ii) Regals Fund; and
- iii) David M. Slager ("Mr. Slager")

#### Item 2(b). Address of Principal Business Office or, if None, Residence

The address of the principal business office of each of Regals Management, Regals Fund and Mr. Slager is 152 West 57th Street, 9th Floor, New York, New York 10019.

#### Item 2(c). Citizenship

- i) Regals Management is a Delaware limited partnership;
- ii) Regals Fund is a Delaware limited partnership; and
- iii) Mr. Slager is a citizen of the Netherlands.

#### Item 2(d). Title of Class of Securities:

Common Stock (the "Common Stock")

### Item 2(e). 68403P104 Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:

Item 4. Ownership:

Item 4(a) **Amount Beneficially Owned:** 

This Item 3 is not applicable.

See Item 9 of the attached cover page.

**CUSIP Number:** 

Item 4(b) **Percent of Class:** 

See Item 11 of the attached cover page.

#### Item 4(c) Number of Shares of which such person has:

(i) Sole power to vote or direct the vote:

See Item 5 of the attached cover page.

(ii) Shared power to vote or direct the vote:

See Item 6 of the attached cover page.

(iii) Sole power to dispose or direct the disposition of:

See Item 7 of the attached cover page.

(iv) Shared power to dispose or direct the disposition of:

See Item 8 of the attached cover page.

Regals Management is the investment manager of Regals Fund, the holder of the Common Stock reported herein. Mr. Slager is the managing member of the general partner of Regals Management. All investment decisions are made by Mr. Slager, and thus the power to vote or direct the votes of the Common Stock reported herein, as well as the power to dispose or direct the disposition of the Common Stock reported herein is held by Mr. Slager through Regals Management.

The 1,376,385 shares of Common Stock beneficially owned by the Reporting Persons consist of: (a) 819,112 shares of Common Stock, and (b) warrants exercisable for 557,273 shares of Common Stock.

#### Item 5. Ownership of Five Percent or Less of a Class:

This Item 5 is not applicable.

#### Item 6. Ownership of More than Five Percent on Behalf of Another Person:

This Item 6 is not applicable.

## Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

This Item 7 is not applicable.

#### Item 8. Identification and Classification of Members of the Group:

This Item 8 is not applicable.

#### Item 9. Notice of Dissolution of Group:

This Item 9 is not applicable.

#### Item 10. Certification:

By signing below each of the Reporting Persons certifies that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### **SIGNATURE**

After reasonable inquiry and to the best of their knowledge and belief, each of the Reporting Persons certifies that the information set forth in this statement is true, complete and correct.

Date: February 6, 2014 REGALS CAPITAL MANAGEMENT LP

By: Regals Capital Holdings LLC,

its general partner

By: /s/ David M. Slager

Name: David M. Slager Title: Managing Member

Date: February 6, 2014 REGALS FUND LP

By: Regals Fund GP LLC, its general partner

By: /s/ David M. Slager

Name: David M. Slager Title: Managing Member

Date: February 6, 2014 DAVID M. SLAGER

By: <u>/s/ David M. Slager</u> Name: David M. Slager

#### EXHIBIT INDEX

Ex.

A. Joint Filing Agreement, dated as of February 6, 2014 by and among Regals Capital Management LP, Regals Fund LP and David
Slager

10

#### **EXHIBIT A**

#### JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock, par value \$0.001 per share, of Oramed Pharmaceuticals, Inc., dated as of February 6, 2014 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Date: February 6, 2014 REGALS CAPITAL MANAGEMENT LP

By: Regals Capital Holdings LLC,

its general partner

By: /s/ David M. Slager

Name: David M. Slager Title: Managing Member

Date: February 6, 2014 REGALS FUND LP

By: Regals Fund GP LLC, its general partner

By: /s/ David M. Slager

Name: David M. Slager Title: Managing Member

Date: February 6, 2014 DAVID M. SLAGER

By: <u>/s/ David M. Slager</u> Name: David M. Slager